Survival of XXXX (prostate, testis and penis) in Europe 1999-2007: Results from the EUROCARE-5 study.

@entity5 @entity1 @entity3930 @entity263
BACKGROUND: We provide updated estimates of survival and survival trends of @entity3930 (prostate, testicular and @entity5 ), in Europe and across European areas. METHODS: The complete approach was used to obtain relative survival estimates for @entity1 diagnosed in 2000-2007, and followed up through 2008 in 29 countries. Data came from 87 @entity5 registries (CRs) for @entity263 and from 86 CRs for testis and penis @entity5 . Relative survival time trends in 1999-2007 were estimated by the period approach. Data came from 49 CRs in 25 countries. RESULTS: We analysed 1,021,275 @entity3930 cases. Five-year relative survival was high and decreased with increasing age for all @entity5 considered. We found limited variation in survival between European regions with Eastern Europe countries having lower survival than the others. Survival for @entity5 @entity1 did not improve from 1999 to 2007. Survival for @entity5 @entity1 remained stable at high levels since 1999. Survival for @entity263 @entity1 increased over time. CONCLUSIONS: Treatment standardisation and centralisation for very rare diseases such as @entity5 or advanced @entity5 should be supported. The high survival of @entity5 makes long-term monitoring of @entity5 survivors necessary and CRs can be an important resource. @entity263 @entity1 ' survival must be interpreted considering incidence and mortality data. The follow-up of the European Randomised Study of Screening for @entity263 should continue to clarify the impact of screening on @entity263 mortality together with population based studies including information on stage and treatments.
